000 01343 a2200385 4500
005 20250515002624.0
264 0 _c20051104
008 200511s 0 0 dut d
022 _a0028-2162
040 _aNLM
_beng
_cNLM
100 1 _aHoogendijk, J E
245 0 0 _a[The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].
_h[electronic resource]
260 _bNederlands tijdschrift voor geneeskunde
_cSep 2005
300 _a2104-11 p.
_bdigital
500 _aPublication Type: English Abstract; Guideline; Journal Article; Practice Guideline
650 0 4 _aAnti-Inflammatory Agents
_xtherapeutic use
650 0 4 _aDermatomyositis
_xdiagnosis
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aHumans
650 0 4 _aMyositis, Inclusion Body
_xdiagnosis
650 0 4 _aNetherlands
650 0 4 _aPolymyositis
_xdiagnosis
650 0 4 _aPractice Patterns, Physicians'
650 0 4 _aPrednisone
_xtherapeutic use
650 0 4 _aPrognosis
650 0 4 _aSocieties, Medical
700 1 _aBijlsma, J W J
700 1 _avan Engelen, B G M
700 1 _aLindeman, E
700 1 _avan Royen-Kerkhof, A
700 1 _ade Rie, M A
700 1 _ade Visser, M
700 1 _aJennekens, F G I
773 0 _tNederlands tijdschrift voor geneeskunde
_gvol. 149
_gno. 38
_gp. 2104-11
999 _c15831755
_d15831755